United Kingdom· GB-APID-40656011000001109
Gavreto 100mg capsules
A pralsetinib product containing pralsetinib, registered in United Kingdom by Blueprint Medicines (UK) Ltd. The same ATC class is registered in 8 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Pralsetinib is registered in 8 of 19 countries.
Countries holding a registration under ATC L01EX23 (pralsetinib), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 6 of them publish a price we can compare per daily dose
Pralsetinib · ATC L01EX23
8 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Franceprice
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Pralsetinib
- Manufacturer
- Blueprint Medicines (UK) Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01EX23
- ATC class
- Pralsetinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07613326045155
- gtin07613326045049
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
93 interactions on record for pralsetinib.
Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pralsetinib · interactions on record
93 records
- 16 severe
- 77 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pralsetinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesGavretoGenentech, Inc.
- SpainGAVRETO 100 MG CAPSULAS DURASBlueprint Medicines (Netherlands) B.V.
- FinlandGavretoBlueprint Medicines Netherlands B.V.
- BelgiumGavreto 100 mgBlueprint Medicines (Netherlands)
- NorwayGavretoRoche
- PolandGavretoRoche Registration GmbH
- FranceGAVRETO 100 mg, géluleBLUEPRINT MEDICINES (PAYS-BAS))
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/383eb7e1-5671-4acf-8fcd-416e6011c69e GET /v1/drugs/383eb7e1-5671-4acf-8fcd-416e6011c69e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40656011000001109",
"desc": "Gavreto 100mg capsules (Blueprint Medicines (UK) Ltd)",
"form": "Oral capsule",
"vpid": "40689111000001109",
"source": "dmd",
"vtm_id": "926318003",
"strength": "100 mg",
"substance": "Pralsetinib",
"ingredient": "Pralsetinib",
"supplier_code": "39059811000001100"
}See everything about pralsetinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.